Haematology

News

Spokesman from MD Anderson Cancer Center

ASH: Regeneron makes frontline case for Lynozyfic in myeloma

Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.

News

ASH: AstraZeneca's dual-wielding CAR-T shows promise

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

News

Lilly gets approval for earlier use of Jaypirca in CLL

Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

ASH: Regeneron makes frontline case for Lynozyfic in myeloma

ASH: AstraZeneca's dual-wielding CAR-T shows promise

Lilly gets approval for earlier use of Jaypirca in CLL

FDA starts priority review of BeOne's Venclexta rival

NICE backs NHS use of Autolus' leukaemia CAR-T

Agios shares slump on sickle cell disease data

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Haematology

Editor's Picks